Clinical Trial Update: BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BMS-986340 in combination with nivolumab, gemcitabine, and nab-paclitaxel for metastatic and recurrent pancreatic adenocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• BMS-986340
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• nivolumab (nivolumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Status: RECRUITING